Vascodagama Online Journal

Hemophilia B Market to Grow at a Substantial Growth Rate During the Forecast Period 2030 – DelveInsight | Key Companies – Pfizer, Novo Nordisk, Bioverativ, CSL Behring, Sanofi, UniQure, and Others

 Breaking News
  • No posts were found

Hemophilia B Market to Grow at a Substantial Growth Rate During the Forecast Period 2030 – DelveInsight | Key Companies – Pfizer, Novo Nordisk, Bioverativ, CSL Behring, Sanofi, UniQure, and Others

December 30
18:09 2021
Hemophilia B Market to Grow at a Substantial Growth Rate During the Forecast Period 2030 -  DelveInsight | Key Companies - Pfizer, Novo Nordisk, Bioverativ, CSL Behring, Sanofi, UniQure, and Others
Delveinsight Business Research LLP
DelveInsight’s “Hemophilia B Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Hemophilia B Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Hemophilia B market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Hemophilia B Market

Hemophilia B: An Overview

According to the Centers for Disease Control and Prevention, Hemophilia B is a genetic disorder caused by missing or defective Factor IX clotting protein. With the lack of this, the blood cannot clot properly to control bleeding like hemophilia A, it is also inherited and is caused by a spontaneous genetic mutation in one-third of the cases. Individuals with hemophilia B do not bleed faster than unaffected individuals, they bleed longer.

The main signs and symptoms of hemophilia are excessive bleeding and easy bruising. The child may suffer from recurrent nose bleeds, blood loss from small cuts, long-term bleeding in the mouth from bites, or after removal of a tooth, on-and-off bleeding from a cut or injury, bleeding within the skin or muscle, and soft tissue that causes a build-up of blood in the area. The diagnosis of hemophilia B is established in individuals with low factor IX clotting activity.

Hemophilia B Market Key Facts

  • According to the World Federation of Hemophilia (WFH), the total number of cases around the World for Hemophilia B in 2018 was 34,289.

  • As per the Centre for Disease Control and Prevention, Hemophilia occurs in about 1 of every 5,000 male births and Hemophilia A is about four times as common as Hemophilia B, and about half of those affected have a severe form. 

  • As per Santoro, Cristina, et al., 2018, the development of an inhibitor in Hemophilia B is a rare event that is., 1.5–3% of all patients but is associated with significant morbidity, related not only to the bleeding risk but also to the frequent occurrence of allergic reactions and nephrotic syndrome.

Hemophilia B Market

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Hemophilia B market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

The report gives a thorough detail of the Hemophilia B market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/hemophilia-b-market

Hemophilia B Epidemiology

The epidemiology section covers insights about the historical and current Hemophilia B patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Hemophilia B Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hemophilia B market or expected to get launched in the market during the study period. The analysis covers Hemophilia B market uptake by drugs; patient uptake by therapies; and sales of each drug.

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Hemophilia B Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Hemophilia B Therapeutics Analysis

The dynamics of the Hemophilia B Therapeutics market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, advancement in the half-life of products, rising awareness of the diseases, incremental healthcare spending across the world, and expected launch of emerging therapies.

Companies across the globe are working towards the development of novel treatment therapies for Hemophilia B. Additionally; some of the companies have recently shifted their focus toward this indication.

Some of the key companies in the Hemophilia B Market include:

  • Sanofi 

  • Alnylam Therapeutics

  • UniQure

  • Freeline Therapeutics

  • Pfizer

  • Novo Nordisk

  • Bioverativ Therapeutics (a Sanofi acquired company)

  • CSL Behring

And others

Hemophilia B Therapies Covered in the report include:

  • Rebinyn

  • Idelvion

  • Alprolix

  • FLT180a

And many others.

Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/hemophilia-b-market

Table of Content

1. Key Insights

2. Executive Summary

3. Hemophilia B Competitive Intelligence Analysis

4. Hemophilia B Market Overview at a Glance

5. Hemophilia B Disease Background and Overview

6. Hemophilia B Patient Journey

7. Hemophilia B Epidemiology and Patient Population

8. Hemophilia B Treatment Algorithm, Current Treatment, and Medical Practices

9. Hemophilia B Unmet Needs

10. Key Endpoints of Hemophilia B Treatment

11. Hemophilia B Marketed Products

12. Hemophilia B Emerging Therapies

13. Hemophilia B Seven Major Market Analysis

14. Attribute Analysis

15. Hemophilia B Market Outlook (7 major markets)

16. Hemophilia B Access and Reimbursement Overview

17. KOL Views on the Hemophilia B Market.

18. Hemophilia B Market Drivers

19. Hemophilia B Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary.

Request Sample Report here:- https://www.delveinsight.com/sample-request/hemophilia-b-market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/